Literature DB >> 27943687

Role of Biologics in Colon Cancer: Still Not Clear.

Chloe E Atreya1, Alan P Venook1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2016        PMID： 27943687      PMCID： PMC5455590          DOI： 10.1200/JOP.2016.018697

Source DB:  PubMed          Journal:  J Oncol Pract        ISSN： 1554-7477            Impact factor:   3.840


× No keyword cloud information.
  7 in total

1.  Expanded RAS: refining the patient population.

Authors:  Chloe E Atreya; Ryan B Corcoran; Scott Kopetz
Journal:  J Clin Oncol       Date:  2015-01-12       Impact factor: 44.544

2.  Cetuximab shows activity in colorectal cancer patients with tumors that do not express the epidermal growth factor receptor by immunohistochemistry.

Authors:  Ki Young Chung; Jinru Shia; Nancy E Kemeny; Manish Shah; Gary K Schwartz; Archie Tse; Audrey Hamilton; Dorothy Pan; Deborah Schrag; Lawrence Schwartz; David S Klimstra; Daniel Fridman; David P Kelsen; Leonard B Saltz
Journal:  J Clin Oncol       Date:  2005-01-27       Impact factor: 44.544

3.  KRAS mutations as an independent prognostic factor in patients with advanced colorectal cancer treated with cetuximab.

Authors:  Astrid Lièvre; Jean-Baptiste Bachet; Valérie Boige; Anne Cayre; Delphine Le Corre; Emmanuel Buc; Marc Ychou; Olivier Bouché; Bruno Landi; Christophe Louvet; Thierry André; Fréderic Bibeau; Marie-Danièle Diebold; Philippe Rougier; Michel Ducreux; Gorana Tomasic; Jean-François Emile; Frédérique Penault-Llorca; Pierre Laurent-Puig
Journal:  J Clin Oncol       Date:  2008-01-20       Impact factor: 44.544

Review 4.  Role of Biologics in First-Line Treatment of Colorectal Cancer.

Authors:  Amit Mahipal; Axel Grothey
Journal:  J Oncol Pract       Date:  2016-12       Impact factor: 3.840

5.  Cetuximab-induced anaphylaxis and IgE specific for galactose-alpha-1,3-galactose.

Authors:  Christine H Chung; Beloo Mirakhur; Emily Chan; Quynh-Thu Le; Jordan Berlin; Michael Morse; Barbara A Murphy; Shama M Satinover; Jacob Hosen; David Mauro; Robbert J Slebos; Qinwei Zhou; Diane Gold; Tina Hatley; Daniel J Hicklin; Thomas A E Platts-Mills
Journal:  N Engl J Med       Date:  2008-03-13       Impact factor: 91.245

6.  Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10.

Authors:  Laurence E McCahill; Greg Yothers; Saima Sharif; Nicholas J Petrelli; Lily Lau Lai; Naftali Bechar; Jeffrey K Giguere; Shaker R Dakhil; Louis Fehrenbacher; Samia H Lopa; Lawrence D Wagman; Michael J O'Connell; Norman Wolmark
Journal:  J Clin Oncol       Date:  2012-08-06       Impact factor: 44.544

7.  Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials.

Authors:  Sabine Tejpar; Sebastian Stintzing; Fortunato Ciardiello; Josep Tabernero; Eric Van Cutsem; Frank Beier; Regina Esser; Heinz-Josef Lenz; Volker Heinemann
Journal:  JAMA Oncol       Date:  2017-02-01       Impact factor: 31.777
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.